Ehnertu for HER-2 low breast cancer – pro
Enhertu (5.4mg/kg) is recently approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. or the first time in a clinical trial, DESTINY-Breast04’s exciting results showed that patients with low HER2-expressing metastatic breast cancer benefitted from a targeted therapy, trastuzumab deruxtecan (T-DXd/Enhertu®), an antibody-drug conjugate (ADC).
S. Modi et al, Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerJuly 7, 2022
N Engl J Med 2022; 387:9-20
Enhertu Prescribing Information 2022